GeoVax Labs, Inc. has officially announced that its Board of Directors authorized a 1-for-24 reverse stock split concerning its issued and outstanding common stock, which carries a par value of $0.001 per share. The biotechnology enterprise is executing the corporate action to restore compliance with the $1.00 minimum bid price mandate required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Stockholders previously granted approval for the reverse split during a meeting conducted on October 27, 2026.
Trading on the split-adjusted structure is scheduled to commence at the market open on the Nasdaq Stock Exchange on November 11, 2026, taking effect officially at 12:01 am Eastern Time on that date. The common stock will preserve its existing ticker symbol "GOVX" while receiving a new CUSIP identifier, 373678 804.
Upon implementation of the reverse split, every 24 issued and outstanding common shares will convert automatically into one single share of common stock, leaving the par value per share unaltered. Consequently, the aggregate number of issued and outstanding common shares will decrease proportionally from 12,209,871 shares to approximately 508,745 shares.
Immediately following the transaction, the percentage ownership and proportional voting power belonging to individual stockholders will remain identical, with the exception of minor variances arising from the rounding of fractional shares up to the nearest whole share. The overall rights and privileges tied to the common stock holdings will stay substantially unchanged.
About the Company
GeoVax Labs, Inc. operates as a clinical-stage biotechnology firm dedicated to creating vaccines and immunotherapies directed at high-consequence infectious diseases and solid tumor cancers. Its primary clinical program centers on GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine designed to protect against mpox and smallpox. This asset moves forward via an expedited regulatory pathway, with management intending to launch a pivotal Phase 3 clinical trial late in 2026 to address broader orthopoxvirus vaccine requirements and biodefense readiness.
Within the oncology space, GeoVax works on Gedeptin, which is a gene-directed enzyme prodrug therapy intended to boost immune checkpoint inhibitor activity. Gedeptin finished a multicenter Phase 1/2 trial involving advanced head and neck cancer patients and is progressing into combination frameworks, encompassing neoadjuvant and first-line treatment plans. The firm maintains an intellectual property portfolio spanning its oncology and infectious disease pipelines while assessing strategic alliances and funding paths.
